Summary Retinoids and vitamin D are important factors that regulate cellular growth and differentiation. An additive growth-inhibitory effect of retinoids and vitamin D analogues has been demonstrated for human myeloma, leukaemic and breast cancer cells. We set out to study the effects of the vitamin D analogue EB1089 and the retinoids all-trans-and 9-cis-retinoic acid on the human pancreatic adenocarcinoma cell lines Capan 1 and Capan 2 and the undifferentiated pancreatic carcinoma cell line Hs766T. The cell lines investigated expressed vitamin D receptor, retinoic acid receptor (RAR)-a and y as determined by polymerase chain reaction after reverse transcription. RAR-f, was expressed only in Hs766T cells. Addition of all-trans-retinoic acid increased the amount of RAR-a mRNA in the three cell lines and induced RAR-,B mRNA in Capan 1 and Capan 2 cells. All-trans-retinoic acid at a concentration of 10 nM inhibited the growth of Capan 1 and Capan 2 cells by 40% relative to controls. 9-cis-Retinoic acid was less effective. Neither all-trans-retinoic acid nor 9-cisretinoic acid affected the growth of Hs766T cells. EB1089, if added alone to the cells, did not significantly inhibit growth. However, the combination of 1 nM EB1089 with 10 nM all-trans-retinoic acid exerted a growthinhibitory effect of 90% in Capan 1 cells and of 70% in Capan 2 cells. Our data suggest that vitamin D analogues together with retinoids inhibit the growth of human pancreatic cancer cells. However, in vivo studies are necessary to examine the potential use of retinoids and vitamin D analogues on pancreatic cancer.
Carcinoma of the pancreas is the fifth leading cause of death from malignant disease in Western society. In the United States incidence of pancreatic carcinoma has trebled in the last 50 years (Kelly and Benjamin, 1995) . Pancreatic carcinoma is associated with an especially poor prognosis (Jeekel, 1994) . Neither radiotherapy nor chemotherapy improve 5 year survival rates, which do not exceed 5% (Wagener et al., 1994> . Therefore new therapeutic modalities are essential for treating pancreatic carcinoma. There has been increasing evidence that the steroid hormones retinoic acid and vitamin D are naturally occurring agents controlling cellular differentiation and proliferation both in normal and malignant cells (Colston, 1993) .
The biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 25(OH) D3] exerts effects unrelated to calcium homeostasis such as inhibiting proliferation of cancer cells (Cross et al., 1992) . Receptors for vitamin D are present in a variety of cancer cells, including pancreatic adenocarcinoma (Reichel et al., 1989 ). However, a major drawback to considering conventional vitamin D metabolites as therapeutic agents is the production of hypercalcaemia at doses more than a few micrograms per day (Reichel et al., 1989) . Recently a number of laboratories have developed synthetic vitamin D analogues that inhibit cancer cell growth, but have reduced calcaemic activity (Colston et al., 1992; Shabahang et al., 1994) . One compound, EB 1089, which is characterised by a modified C17 side chain of the vitamin D molecule, inhibits the growth of breast cancer cells in vitro and in vivo (Colston et al., 1992) .
Retinoids are natural and synthetic derivatives to vitamin A (Bollag and Holdener, 1992) . They elicit a large array of biological responses during morphogenesis and differentiation (Sporn and Roberts, 1983) . Knowledge of the effects of these compounds has led to the assumption that retinoids may act as chemopreventive agents as well as inhibitors of tumour growth (Bollag and Holdener, 1992) . Retinoids have been shown to depress tumour incidence and size in animal models (Gudas, 1992) . Studies with cancer cells demonstrate growth inhibition induced by retinoids (Eliason et al., 1993; Peehl et al., 1994) .
Combining retinoids with cytokines such as interferon leads to enhanced effects on tumours in vitro and in vivo (Bollag and Peck, 1994) . Additionally, recent investigations have shown that retinoids together with vitamin D analogues induce additive growth inhibition of myeloma cells, leukaemic cells and breast cancer cells (Dore et al., 1993; Lutzky et al., 1994; Bollag and Peck, 1994) .
We set out to study the effects of the retinoids all-transretinoic acid, 9-cis-retinoic acid and the vitamin D analogue EB1089 on three human pancreatic cell lines, two were derived from adenocarcinomas and one was derived from an undifferentiated carcinoma. 
Materials and methods

Anchorage-dependent growth assays
We studied the effects of all-trans-retinoic acid, 9-cis-retinoic acid and the vitamin D analogue EB1089 on the anchorageindependent growth of the human pancreatic adenocarcinoma cell lines Capan 1, Capan 2 and the undifferentiated human pancreatic carcinoma cell line Hs766T. Cells were incubated with concentrations of retinoids and EB1089 ranging from 1 pM to 1 ,UM. After 7 days of incubation cell number was quantified and compared with that in medium without added hormone. The anti-proliferative effects of alltrans-retinoic acid and 9-cis-retinoic acid were dose dependent (Figures 1 and 2 ). All-trans-retinioc acid at a concentration of 10 nM inhibited the growth of the pancreatic adenocarcinoma cell lines Capan 1 and Capan 2 by 40% relative to untreated controls (Figure 1 ). 9-cis-retinoic acid at the same concentration affected the growth by 25% as compared with untreated controls (Figure 2) . The growth of the undifferentiated pancreatic carcinoma cell line Hs766T
was not affected by all-trans-or 9-cis-retinoic acid (data not shown). The vitamin D analogue EB 1089 had a maximal growth inhibitory effect of 25%, which was reached at a concentration of 1 nM in all three cell lines (Figure 3 , shown for Capan 1 cells). Increasing concentrations of EB1089 did not enhance this effect (Figure 3) , however, EB1089 potentiated the effects of all-trans-and 9-cis-retinoic acid (Figure 4 ). In the presence of 1 nM EB1089 all-trans-retinoic acid, at a concentration of 10 nM, induced an inhibition of 90% of growth in Capan 1 cells and an inhibition of 70% of growth in Capan 2 cells (Figure 4) . 9-cis-Retinoic acid (10 nM) in the presence of 1 nM EB1089 was not as effective as all-trans-retinoic acid (Figure. 4) . Vitamin D3 had the same effects on growth as EB1089 (data not shown). All-transretinoic acid up to a concentration of 1000 nM did not reduce Expression of receptor mRNA Total RNA was extracted from the three human pancreatic cancer cell lines Capan 1, Capan 2 and Hs766T. RNA was transcribed into cDNA and then amplified using gene-specific primer pairs and polymerase chain reaction methodology. For RAR-a a specific amplification product could be easily detected corresponding in size to the product described by Pfeffer et al. (1995) Figure 1 Effects of all-trans-retinoic acid on the anchoragedependent growth of Capan 1 (a) and Capan 2 (El) cells. Cells were plated in triplicate in RPMI medium supplemented with 10% fetal bovine serum (FBS). After 24h compounds were added. Fresh glutamine was added every 2 days. Cells were counted after 7-9 days. Standard deviations were 5-10%. Viability as determined by trypan blue exclusion was 90% in untreated and treated cells. Experiments were conducted as described in Figure 1 .
9-cisretinoic acid (nM) Figure 4 Inhibitory effects of all-trans-retinoic acid and 9-cis retinoic acid on the anchorage-dependent growth of Capan 1 (a) and Capan 2 (El) cells in the presence of 1 nM EB1089. Experiments were conducted as described in Figure 1 . weak signal of RAR-f3 and RAR-y (data not shown), we applied a seminested PCR as second amplification step for detection of the mRNA of these two receptors. Using this approach the three cell lines showed a strong signal of RARy mRNA (Figure 6 ) corresponding to the specific product described earlier in ovarian cancer cells (Harant et al., 1993) .
In contrast, we found differential expression of RAR-fl mRNA, which could be detected only in Hs766T cells, matching the product described previously (Harant et al., 1993) but neither in Capan 1 nor in Capan 2 cells (Figure 6 ).
Addition of 10 nM all-trans-retinoic acid induced RAR-fl expression in Capan 1 (Figure 7) and Capan 2 cells (not shown) but did not affect RAR-fl expression in Hs766T cells (Figure 7) . Expression of,2-microglobulin mRNA measured after only 20 cycles of amplification was used as an internal control that showed a similar intensity in all samples tested, suggesting quantitative comparable PCR reactions (Figure 7 ). For expression of vitamin D receptor mRNA a signal was obtained in all cell lines using PCR after reverse transcription (Figure 8) , which was the size expected from the cDNA sequence published earlier (Evans, 1988) .
Discussion
Pancreatic cancer is poorly influenced by chemotherapy (Jeekel, 1994) (Reichel et al., 1989; Cross et al., 1992; Bollag and Holdener, 1992; Gudas, 1992 (Harant et al., 1993) , breast cancer cell lines (Roman et al., 1992) , myeloma cells and leukaemic cells (Lutzky et al., 1994; Dore et al., 1993) . There is no correlation between biological effects of retinoids and degree of receptor expression (van-der Leede et al., 1993; Lutzky et al., 1994) , which is consistent with our results. A lack of retinoic acid receptor subgroups such as RAR-1 has been described in malignant tumours (Gudas, 1992; Xu et al., 1994; Swisshelm et al., 1994) . have not determined the expression of RXR, because its ligand, 9-cis-retinoic acid, does not exert a significant biological effect at physiological concentrations (Figure 2 ).
Vitamin D has been shown to inhibit growth of human colon carcinoma cells (Shabahang et al., 1993) and to induce regression of T-cell lymphoma of the skin (Scott-Mackie et al., 1993) . Receptors for vitamin D are present in a variety of cancer cell lines, including prostate carcinoma (Miller et al.. 1992) , pancreatic carcinoma, osteosarcoma, melanoma, breast carcinoma, colon carcinoma, thyroid carcinoma, bladder carcinoma, cervical carcinoma and fibrosarcoma (Reichel et al., 1989) . Recently a new vitamin D analogue, EB 1089, has been developed (Colston et al., 1992) . EB 1089 is a potent inhibitor of proliferation of breast cancer cells in vitro and in vivo (Colston et al., 1992) . Other vitamin D analogues have been developed that significantly inhibit the growth of human colon cancer cells in vitro (Cross et al., 1992; Shabahang et al., 1994) . These analogues reduce the growth rate twice as effectively as does dihydroxyvitamin D3 (Shabahang et al., 1994 ). Although we have demonstrated expression of vitamin D receptor (Figure 8 ), the analogue EB 1089 (Figure 3) as well as 1,25-dihydroxyvitamin D3 do not significantly inhibit the growth of human pancreatic carcinoma cells.
Combinations of retinoids with various compounds lead to enhanced anti-tumour activities (Bollag and Peck, 1994) . In clinical trials retinoids have been mostly used together with interferon. The best results have been achieved in squamous cell carcinomas of the skin and the cervix (Bollag and Peck, 1994 (Bollag and Peck, 1994) .
Additional in vitro investigations and tests in animal models will be needed to clarify the potential role of vitamin D analogues and retinoids in the therapy of pancreatic cancer.
